Company Overview - Nasus Pharma Ltd. is a clinical-stage pharmaceutical company focused on developing innovative intranasal products for emergency medical conditions [3] - The company is developing NS002, an intranasal powder Epinephrine product candidate, as a needle-free alternative to traditional Epinephrine autoinjectors for anaphylaxis treatment [3] - Nasus Pharma utilizes proprietary powder-based intranasal (PBI) technology designed for rapid and reliable drug delivery, leveraging the nasal cavity's vascular network for quick absorption [3] Conference Participation - Company management will present at the H.C. Wainwright 27th Annual Global Investment Conference [1] - Management will be available for one-on-one meetings during the conference, and interested investors are encouraged to contact their representatives at sponsoring institutions [2] - The company presentation is scheduled for September 5, 2025, from 07:00 to 07:30 a.m. ET, with CEO Dan Teleman as the presenter [4]